CD39 and PD-L1 co-expression may serve as potential indicators for evaluating the efficacy of neoadjuvant immunotherapy in esophageal squamous cell carcinoma
Hao Wu, Zhenyu Han, Jianmin Wu, Yujin Zhang et autres
Esophageal squamous cell carcinoma (ESCC) contributes a major therapeutic challenge in gastrointestinal oncology due to its aggressive behavior. Neoadjuvant immunotherapy combined with chemotherapy (NIT) has emerged as a novel treatment strategy for ESCC. However, clinical responses to NIT vary substantially among individuals, …
cn (code pays fourni par la source)
0 citations
Diseases of the Esophagus